Red light therapy, when used at the wavelengths and doses studied in clinical settings, does not appear to worsen melasma and may actually help reduce it. That said, the answer is more layered than a simple “no.” Melasma is driven by a surprisingly complex set of factors beyond just pigment-producing cells, and not all light in the visible spectrum affects skin the same way. The difference between a wavelength that calms pigmentation and one that triggers it can be narrower than most people realize, which is why the details matter.
Why Melasma Reacts to Light in the First Place
Melasma is not simply a case of overactive pigment cells. The patches of darkened skin sit on top of a whole neighborhood of changes in the deeper layers: damaged elastic fibers (a hallmark of chronic sun exposure), a disrupted boundary between the outer and inner layers of skin, and extra blood vessels feeding the area.1PubMed Central. Unraveling Melasma: From Epidermal Pigmentation to Microenvironmental Dysregulation Mast cells and aging fibroblasts also play roles, creating a micro-environment that keeps the pigment coming back even after treatments that lighten the surface.2PubMed Central. Pathogenesis of Melasma Explained
This is why melasma is notoriously stubborn and why it responds so strongly to light exposure. Ultraviolet radiation has long been recognized as the primary trigger, but in recent years researchers have shown that visible light, particularly the shorter-wavelength blue and violet end of the spectrum (roughly 400 to 500 nanometers), can also drive pigmentation. High-energy visible light activates a receptor called Opsin 3 in melanocytes, which ramps up the enzyme tyrosinase and pushes melanin production into high gear.3PubMed Central. Melasma: The need for tailored photoprotection to improve clinical outcomes This effect is especially pronounced in people with darker skin tones (Fitzpatrick phototypes III through V), while those with very fair skin seem largely unaffected by blue-violet light exposure.3PubMed Central. Melasma: The need for tailored photoprotection to improve clinical outcomes
This is the crux of the concern about red light therapy. If visible light can worsen melasma, does that include the red part of the spectrum? The short answer is that the mechanisms driving light-induced pigmentation are wavelength-specific, and the biology at the red end of the spectrum is meaningfully different from what happens at the blue end.
How Red Light Therapy Actually Works on Cells
Red light therapy, more formally called photobiomodulation, uses wavelengths typically between 600 and 1,000 nanometers. The primary target inside cells is an enzyme called cytochrome c oxidase, which sits in the energy-producing machinery of mitochondria. This enzyme has metal centers that absorb photons in the red and near-infrared range. When light hits it, the enzyme shakes loose nitric oxide molecules that were slowing it down, speeds up electron flow, and boosts the cell’s energy production.4PubMed Central. Molecular Mechanisms of Photobiomodulation in Retinal Diseases: Cytochrome c Oxidase, Mitochondrial Bioenergetics and Cytoprotective Signalling The downstream effects include reduced inflammation, improved antioxidant defenses, and changes in how cells grow and repair themselves.5PubMed Central. What Lies at the Heart of Photobiomodulation: Light, Cytochrome C Oxidase, and Nitric Oxide-Review of the Evidence
This is a fundamentally different mechanism from the Opsin 3 pathway that blue light uses to trigger pigmentation. Red light does not efficiently activate Opsin 3. Instead of telling melanocytes to produce more melanin, the energy boost from red light appears to affect how cells repair, regulate inflammation, and manage blood vessel behavior. For melasma, where inflammation, blood vessels, and damaged tissue all play supporting roles, this distinction is critical.
The Opsin 3 Question and Wavelength Specificity
The discovery of Opsin 3’s role in pigmentation has reshaped how dermatologists think about light and melasma. Opsin 3 responds to shorter visible wavelengths, particularly blue light around 415 to 465 nanometers, triggering a calcium-dependent cascade that ends with more tyrosinase and more melanin.6PubMed. Melanocytes Sense Blue Light and Regulate Pigmentation through Opsin-3 This is the pathway that makes screen time and indoor lighting a legitimate (if minor) concern for melasma patients, and it is the pathway that makes people nervous about any light-based therapy.
Interestingly, one research group found that Opsin 3 actually acts as a negative regulator of melanin production through a separate, light-independent pathway involving the melanocortin 1 receptor. In that role, Opsin 3 dampens the signals that drive pigment synthesis.7PubMed Central. Human nonvisual opsin 3 regulates pigmentation of epidermal melanocytes through functional interaction with melanocortin 1 receptor The science here is still being sorted out, and the interplay between Opsin 3’s light-dependent and light-independent roles is genuinely complicated. But the key takeaway for red light therapy users is that the pro-pigmentation opsin pathway is primarily a short-wavelength phenomenon. Red light at 630 nanometers and near-infrared at 830 or 850 nanometers sit well outside the range that most efficiently activates this pigmentation cascade.
What the Clinical Studies Show
A 2023 integrative review that pooled findings from laboratory experiments, animal models, and clinical trials concluded that photobiomodulation effectively reduces melasma-related hyperpigmentation. The wavelengths that showed benefit included red light at 630 nanometers, amber light at 585 to 590 nanometers, and near-infrared at 830 and 850 nanometers, all delivered at energy doses between 1 and 20 joules per square centimeter. These wavelengths reduced tyrosinase activity, melanin content, and the expression of genes involved in pigment production. The review also noted improvements in the deeper structural problems associated with melasma, including reduced redness and new blood vessel formation.8PubMed. Photobiomodulation for melasma treatment: Integrative review and state of the art
A pilot study using pulsed photobiomodulation on one side of the face while the other served as a control found that the treated side showed a significant drop in pigmentation scores over 12 weeks, going from roughly 11.4 to 4.7 on their measurement scale. The study also suggested that photobiomodulation improved the skin’s resistance to subsequent sun exposure, which is a meaningful finding given how easily melasma flares after UV exposure.9Journal of Clinical and Aesthetic Dermatology. Dual Effect of Photobiomodulation on Melasma: Downregulation of Hyperpigmentation and Enhanced Solar Resistance—A Pilot Study That said, this was a small pilot, and the effect sizes from any single trial should be taken as promising rather than definitive.
These results might seem counterintuitive. How can shining light on a light-sensitive condition make it better? The answer lies in photobiomodulation’s anti-inflammatory effects and its ability to address the vascular and structural components of melasma rather than simply targeting pigment. Instead of stimulating melanocytes through opsin-mediated pathways, the red and near-infrared wavelengths seem to calm the surrounding environment that keeps melanocytes in overdrive.
The Dose Problem and Biphasic Response
Here is where the “it depends” caveat earns its keep. Photobiomodulation follows a biphasic dose-response pattern, sometimes called the Arndt-Schulz curve. Low doses tend to stimulate beneficial effects in tissues, while higher doses can inhibit or damage them.10PubMed Central. Biphasic dose response in low level light therapy This has been confirmed in cell studies where fibroblast growth and mitochondrial activity increased at lower energy levels but dropped at higher ones.11PubMed. Biphasic Dose/Response of Photobiomodulation Therapy on Culture of Human Fibroblasts Similar biphasic effects have been observed with near-infrared light and oxidative stress in blood cells.12PubMed. Biphasic dose-response and effects of near-infrared photobiomodulation on erythrocytes susceptibility to oxidative stress in vitro
For someone using red light therapy at home, this matters a great deal. The clinical studies showing melasma improvement used carefully controlled energy doses, generally under 20 joules per square centimeter. Consumer devices vary enormously in power output, and the instinct to use a device longer or hold it closer in hopes of faster results could push past the beneficial window. Too much energy can flip the response from anti-inflammatory to pro-inflammatory, and inflammation is one of the key drivers of melasma recurrence. There is no published threshold where red light definitively starts making melasma worse, because the research has not been designed to find that boundary. But the biphasic principle means the boundary exists.
The Vascular Angle
One of the more underappreciated aspects of melasma is the role of blood vessels. Melasma patches tend to have more dilated capillaries than the surrounding skin, and the cells lining those vessels secrete signaling molecules that can stimulate melanocytes to produce more pigment.13Wiley Online Library. Characteristics of dermal vascularity in melasma and solar lentigo This is why some dermatologists have started combining pigment-focused treatments with vascular laser therapies, and it is a reason that photobiomodulation’s ability to reduce redness and new blood vessel formation may contribute to its benefits in melasma.8PubMed. Photobiomodulation for melasma treatment: Integrative review and state of the art
However, near-infrared light can cause visible flushing and increased blood flow to the skin’s surface.14PubMed. Near-infrared heating of skin to delineate non-melanoma skin cancer lesions: A pilot study Whether temporary redness from a therapy session translates to long-term vascular changes that worsen melasma is not established, but it is a reasonable concern, particularly if someone is using high-powered devices or long treatment sessions that heat the skin. Any device or protocol that makes your melasma patches visibly redder or warm during treatment is worth discussing with a dermatologist before continuing.
Heat, TRPV1 Channels, and Melanin
Related to the vascular question is the issue of heat. Some red light and near-infrared devices, especially panels designed for large body areas, generate enough thermal energy to noticeably warm the skin. This matters because melanocytes have temperature-sensitive receptors called TRPV1 channels. Research has shown that activating TRPV1 alone does not trigger melanin production, but it can amplify UV-driven pigmentation and boost melanin synthesis through non-UV pathways when other signals are present.15PubMed. Transient Receptor Potential channels, TRPV1 and TRPA1 in melanocytes synergize UV-dependent and UV-independent melanogenesis
In practical terms, this means that heat from a red light device probably will not trigger a melasma flare on its own, but it could make your skin more reactive to other pigmentation triggers you encounter afterward, like sunlight. If you are using a powerful panel and your face feels warm, the thermal component becomes a variable that the controlled clinical studies (which use lower-power, often pulsed devices) did not account for. Keeping sessions short enough that the skin does not heat up significantly is a reasonable precaution.
Skin Tone and Individual Risk
Melasma disproportionately affects people with medium to dark skin tones, and skin type plays into how light-based treatments perform. Intense pulsed light therapy, which uses a broad spectrum that includes shorter visible wavelengths, is generally considered better suited for lighter skin types (Fitzpatrick I through III) because it risks targeting the normal background pigment in darker skin.16PubMed Central. A review of laser and light therapy in melasma Red light therapy is not the same technology as intense pulsed light, and its longer wavelengths are less absorbed by melanin, which in theory makes it safer across a wider range of skin tones. Still, the clinical evidence for photobiomodulation in melasma has come from relatively small studies, and the data on darker skin types specifically is thin. People with Fitzpatrick V or VI skin should be cautious about extrapolating results from studies that may have included mostly lighter-skinned participants.
Post-inflammatory hyperpigmentation is another concern worth mentioning. Any treatment that irritates or inflames the skin can trigger a darkening response, especially in darker skin tones.17PubMed. Prophylaxis of Post-Inflammatory Hyperpigmentation From Energy-Based Device Treatments: A Review Red light therapy at appropriate doses is specifically designed to be non-damaging and non-ablative, which should minimize this risk. But poorly calibrated devices, overly aggressive protocols, or combining red light with sensitizing topicals could cross the irritation threshold.
Combining Red Light Therapy with Topical Treatments
Many people treating melasma use topical agents like hydroquinone, tretinoin, azelaic acid, or vitamin C. A natural question is whether red light therapy can be layered on top of these. The concern is less about a direct chemical interaction and more about cumulative skin sensitivity. Hydroquinone in particular increases the skin’s sensitivity to light, and while red light lacks the UV component that makes sunlight dangerous for sensitized skin, it still introduces photon energy into tissue that may already be more reactive than usual. For someone whose skin is prone to irritation, adding red light therapy on top of a sensitizing topical regimen could cause redness or discomfort that would not occur with either treatment alone.
Timing matters here. If you are using tretinoin at night and a red light device in the morning, the overlap in skin sensitivity is less of an issue than applying hydroquinone and immediately sitting in front of a panel. There is no well-powered study specifically examining the interaction between common melasma topicals and photobiomodulation, so the advice is largely based on general dermatologic principles: introduce one new treatment at a time, start with shorter sessions, and monitor for irritation.
Circadian Rhythms and When You Treat
An emerging area of research connects the skin’s internal clock to melanin production. Melanocytes express circadian genes, and disrupting the normal light-dark cycle can alter how much pigment they produce. In laboratory models, melanin synthesis was inhibited when the circadian cycle was disrupted through continuous light or continuous darkness, or through pharmacological manipulation of clock proteins.18PubMed Central. Interplay of Light, Melatonin, and Circadian Genes in Skin Pigmentation Regulation
What this means for red light therapy timing is not yet clear, but it raises interesting questions. The skin’s pigmentation machinery does not operate identically at all hours. Whether morning versus evening use of a red light device produces different outcomes in melasma patients has not been tested directly. For now, this is a watch-this-space finding rather than something that should change your routine, but it does suggest that the timing of light exposure, not just its wavelength and dose, may eventually become part of the clinical conversation around melasma management.
What “Different Visible Light Wavelengths” Actually Means for Your Skin
Consumer confusion about visible light and melasma often comes from treating the entire visible spectrum as one thing. It is not. Different wavelengths of visible light interact with different molecular targets in the skin and can have opposing effects on pigmentation.19PubMed Central. The Emerging Role of Visible Light in Melanocyte Biology and Skin Pigmentary Disorders: Friend or Foe? Blue and violet wavelengths around 400 to 500 nanometers are the primary culprits for visible-light-induced hyperpigmentation, working through the Opsin 3 pathway. Amber light around 585 to 590 nanometers and red light at 630 nanometers, by contrast, have shown melanin-reducing effects in both lab and clinical studies.8PubMed. Photobiomodulation for melasma treatment: Integrative review and state of the art
This is why blanket advice to “avoid visible light” if you have melasma, while well-intentioned, is an oversimplification. It is the blue end of the spectrum that deserves caution, not the red end. Tinted sunscreens with iron oxides that filter blue and violet light are genuinely useful for melasma protection. But avoiding a red light therapy device purely because it emits “visible light” conflates two very different biological interactions. The devices to be cautious about are LED masks or panels that include blue or white LEDs alongside the red ones, since those shorter wavelengths could counteract any benefit from the red light.
Devices and the Gap Between Clinic and Home
Clinical studies on photobiomodulation for melasma use medical-grade devices with precise wavelength outputs, calibrated power densities, and controlled treatment durations. Consumer devices range from inexpensive handheld wands to large panel arrays, and their specifications do not always match what was studied. Some panels emit wavelengths across a broader band than advertised, and few consumer products undergo independent verification of their spectral output. A device marketed as “red light” might include amber, orange, or even some shorter-wavelength spillover depending on the LED quality.
Power density is another variable. A device that delivers 5 milliwatts per square centimeter at the skin’s surface behaves very differently from one delivering 100 milliwatts per square centimeter, even at the same wavelength. The clinical studies showing melasma improvement used specific energy doses (measured in joules per square centimeter), and achieving the same dose with a lower-power device means longer treatment times, which changes how the skin absorbs and distributes the energy. None of this means consumer devices are useless, but it does mean that the confident claims made by device manufacturers do not always map onto the evidence from controlled studies. If you are treating melasma specifically, a dermatologist who uses medical-grade photobiomodulation equipment can control these variables in ways that are difficult to replicate at home.